EAM Investors’s Replimune Group REPL Stock Holding History

EAM Investors’s Portfolio REPL Stock Details REPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88,078	Closed	-$2.4M	–	345
2022 Q4	$2.4M	Buy	+88,078	New	+$1.83M	0.5%	65
2020 Q4	–	Sell	-37,942	Closed	-$873K	–	375
2020 Q3	$873K	Sell	37,942 -19,144	-34%	-$436K	0.21%	232
2020 Q2	$1.42M	Buy	+57,086	New	+$1.01M	0.31%	155

Other funds holding REPL

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EAM Investors's REPL Position: Q1 2023 in Review

EAM Investors sold out of Replimune Group (REPL) in Q1 2023, closing a stake of 88,078 shares — an estimated $2.4M sold.

EAM Investors first reported a position in REPL in Q2 2020 and held it in 3 quarters. The position peaked at $2.4M in Q4 2022. 140 funds tracked by Wall St. Rank hold REPL as of Q1 2023.

EAM Investors reported no remaining Replimune Group position as of Q1 2023 after selling out during the quarter.
EAM Investors sold 88,078 Replimune Group shares in Q1 2023, an estimated $2.4M.
EAM Investors first reported a position in Replimune Group in Q2 2020 and held it in 3 quarters.
EAM Investors's Replimune Group position peaked at $2.4M in Q4 2022.
140 funds tracked by Wall St. Rank held Replimune Group as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.